Skip to main content

Corporate & Cultural Convergence in Life Sciences M&A


Date: July 30, 2020

Time: 12:00PM - 1:00PM (EST)

Location: View the Webinar Recording

M&A plays an important role in enabling the life sciences ecosystem and is one of the primary routes by which treatments are acquired, nurtured, and brought to market. But what happens after these deals get done? And how can these transactions be more successful for the buyer and seller?

Mintz hosted a webinar discussion that shared a variety of perspectives on M&A transactions, including buy-side and sell-side considerations and experiences. Our panelists addressed:

  • Recent findings from a newly published report from Mintz and Mergermarket
    providing insight based on interviews with 100 senior-level US executives about their latest deals as well as data on M&A transactions in the life sciences industry
  • Deal drivers in 2020: What is motivating M&A activity now?
  • Lessons learned from post-merger integrations and challenges associated with combining organizations
  • Avoid post-closing disputes


Joshua Fox Headshot

Joshua D. Fox


Joshua D. Fox is a corporate attorney at Mintz who represents clients in milestone transactions and general corporate matters throughout the business lifecycle. He focuses on the life sciences (biotechnology, diagnostics, devices) and tech industry, including digital health, software, technology-enabled services, and consumer products.

Claire Rychlewski


Deputy Editor, Mergermarket

Tom Burke


Chief Financial Officer, ButcherBox; formerly with Hydra Biosciences and Infinity Pharmaceuticals

Joseph LaPlume


Corporate Executive Vice President, Charles River Laboratories